Silva Julianna Henriques da, Abreu Leticia Coli Louvisse de, Ferrari Renato, Quintana Celia Yelimar Palmero, Barros Eliane Gouvêa de Oliveira, Cordeiro Natália de Moraes, Pontes Bruno, Sousa Valeria Pereira de, Cabral Lucio Mendes, Fernandes Patricia Dias, Nasciutti Luiz Eurico
Universidade Federal do Rio de Janeiro, Instituto de Ciências Biomédicas, Programa de Pesquisa em Biologia Celular e do Desenvolvimento, Rio de Janeiro 21.941-902, Brazil.
Universidade Federal do Rio de Janeiro, Faculdade de Farmácia, Laboratório de Tecnologia Farmacêutica, Rio de Janeiro 21.941-902, Brazil.
Pharmaceuticals (Basel). 2022 Nov 15;15(11):1414. doi: 10.3390/ph15111414.
Current drugs for the treatment of endometriosis are not able to completely cure the condition, and significant side effects hinder the continuation of treatment. Therefore, it is necessary to search for new drug candidates. In the present paper, the use of plant extracts is highlighted. Babassu oil and Copaiba oil resin have several therapeutic properties. We investigated the in vitro effects of two nanoemulsions containing oil extracted from Babassu () nuts (called SNEDDS-18) and/or oil resin extracted from Copaiba trunk () (called SNEDDS-18/COPA) on cultured human eutopic endometrium stromal cells from endometrial biopsies of patients without (CESC) and with (EuESC) endometriosis as well as human stromal cells from biopsies of endometriotic lesions (EctESC).
CESC, EuESC, and EctESC were taken and treated with SNEDDS-18 and SNEDDS-18/COPA to evaluate their effects on cytotoxicity, cell morphology, proliferation, and signaling pathways.
After 48 h of incubation with SNEDDS-18 and SNEDDS-18/COPA, cell viability and proliferation were inhibited, especially in EctESC. The lowest concentration of both nanoemulsions reduced cell viability and proliferation and broke down the cytoskeleton in EctESCs. After 24 h of treatment a decrease in IL-1, TNF-α, and MCP-1 was observed, as well as an increase in IL-10 production.
Both nanoemulsions can affect endometriotic stromal cell behaviors, thus revealing two potential candidates for new phytotherapeutic agents for the management of endometriosis.
目前用于治疗子宫内膜异位症的药物无法完全治愈该疾病，且显著的副作用阻碍了治疗的持续进行。因此，有必要寻找新的候选药物。在本文中，突出了植物提取物的应用。巴巴苏油和苦配巴油树脂具有多种治疗特性。我们研究了两种纳米乳剂的体外作用，这两种纳米乳剂分别含有从巴巴苏（）坚果中提取的油（称为SNEDDS - 18）和/或从苦配巴树干（）中提取的油树脂（称为SNEDDS - 18/COPA），对来自无子宫内膜异位症患者（CESC）和有子宫内膜异位症患者（EuESC）的子宫内膜活检组织中培养的人在位子宫内膜基质细胞以及来自子宫内膜异位症病变活检组织的人基质细胞（EctESC）的影响。
获取CESC、EuESC和EctESC，并用SNEDDS - 18和SNEDDS - 18/COPA进行处理，以评估它们对细胞毒性、细胞形态、增殖和信号通路的影响。
用SNEDDS - 18和SNEDDS - 18/COPA孵育48小时后，细胞活力和增殖受到抑制，尤其是在EctESC中。两种纳米乳剂的最低浓度降低了EctESC的细胞活力和增殖，并破坏了细胞骨架。处理24小时后，观察到IL - 1、TNF -α和MCP - 1减少，以及IL - 10产生增加。
两种纳米乳剂均可影响子宫内膜异位症基质细胞的行为，从而揭示了两种用于管理子宫内膜异位症的新型植物治疗剂的潜在候选物。
